CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to DSKYF

Trastuzumab Deruxtecan

Phase 3
Daiichi Sankyo (DSKYF)

Phase 3

Development Phase

7

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Q4 '27
DSKYFPhase 2

Trastuzumab deruxtecan Phase 2 Est. Readout (ANISE)

Trastuzumab Deruxtecan
Q4 2027~Q
CT.gov
00%
Q4 '27
DSKYFPhase 3

Trastuzumab Deruxtecan Phase 3 Est. Readout

Trastuzumab Deruxtecan
Q4 2027~Q
CT.gov
00%
May '27
DSKYFPhase 2

Trastuzumab deruxtecan Phase 2 Est. Readout (DG-03)

Trastuzumab Deruxtecan
May 2027~
CT.gov
00%
May '27
DSKYFPhase 3

Trastuzumab deruxtecan Phase 3 Est. Readout

Trastuzumab Deruxtecan
May 2027~
CT.gov
00%
Mar '27
DSKYFPhase 2

Trastuzumab deruxtecan Phase 2 Est. Readout (DPT02)

Trastuzumab Deruxtecan
Mar 2027~
CT.gov
00%
Feb '27
DSKYFPhase 2

Trastuzumab deruxtecan Phase 2 Est. Readout

Trastuzumab Deruxtecan
Feb 2027~
CT.gov
00%
Dec '26
DSKYFPhase 2

Trastuzumab Deruxtecan Phase 2 Est. Readout

Trastuzumab Deruxtecan
Dec 2026~
CT.gov
00%
Competitive Landscape
Drug Information

Target Indication

Gastric Cancer

Clinical Trial

NCT06731478

Last updated: 12/23/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.